- Pegaptanib sodium (Macugen)
- Verteporfin (Visudyne PDT)
- Ranibizumab (Lucentis)
- Bevacizumab (Avastin)
- All of the above
Correct Answer: Bevacizumab (Avastin)
Bevacizumab given intravitreally is a common off-label treatment for all CNV lesion subtypes in any fundus location in neovascular AMD, but is not specifically FDA approved for this indication.